Sanford Health shakes up C-suite
CEO Bill Gassen told employees that “new voices” on the executive team would help the nonprofit health system remain agile in the years ahead.
Medical credit cards ‘exploit loopholes’ in healthcare debt protection, report finds
The credit cards, which can promise patients deceptive no- or low-interest rates, are increasingly being offered in hospitals and physician offices.
CVS shuffles C-suite, appoints CFO as head of health services
Shawn Guertin will now helm the healthcare giant’s suite of care delivery businesses, including Oak Street and Signify, as CVS undergoes a major corporate restructuring following flagging profits.
Walgreens to pay $44M to settle claims over fraudulent Theranos tests
Patients who bought a Theranos blood test would receive double the amount they paid for it.
MA enrollment in rural areas quadrupled since 2010, KFF finds
Forty percent of eligible beneficiaries in rural areas enrolled in a Medicare Advantage plan in 2023 compared with 11% in 2010.
FDA proposes 3 guidances to improve 510(k) clearance process
The agency has made recommendations for selecting predicate devices, using clinical data and conducting performance testing for implants.
Nationwide telehealth use held steady in June
The report from Fair Health comes after lawmakers this summer reintroduced legislation to make pandemic-era telehealth flexibilities permanent.
‘Revolving door’ between HHS and industry could influence regulation, study says
Thirty-two percent of people appointed to positions at the HHS between 2004 and 2020 exited to the private sector, raising concerns about objectivity, according to new research.
Unionized nursing homes more likely to comply with OSHA reporting requirements
Only 40% of nursing homes nationwide complied with reporting requirements between 2016 and 2021, despite nursing homes being among the most dangerous workplaces in America, according to the Health Affairs study.
Astellas withdraws lawsuit challenging Medicare drug price program
Contrary to the drugmaker’s expectations, its top-selling cancer medicine Xtandi wasn’t picked as one of the first 10 drugs to face price negotiations.